Clinical Trials Logo

Renal Insufficiency, Chronic clinical trials

View clinical trials related to Renal Insufficiency, Chronic.

Filter by:

NCT ID: NCT04991571 Completed - Clinical trials for Chronic Kidney Disease

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

Start date: July 29, 2021
Phase: Phase 1
Study type: Interventional

The study will have 2 independent parts: Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan. Part 2 of the study is designed to evaluate the relative bioavailability of zibotentan and dapagliflozin after dosing with two different fixed-dose combination (FDC) formulations and dosing with separate formulations of zibotentan and dapagliflozin.

NCT ID: NCT04990427 Completed - Clinical trials for Chronic Kidney Diseases

CLBS201 in Patients With Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

Start date: January 10, 2022
Phase: Phase 1
Study type: Interventional

CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.

NCT ID: NCT04987242 Completed - Clinical trials for Chronic Kidney Diseases

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

Start date: July 16, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this Phase IIa study is to evaluate the safety and tolerability of ALLN-346 in subjects with hyperuricemia in an inpatient, controlled setting.

NCT ID: NCT04983160 Completed - Clinical trials for Chronic Kidney Disease

Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial

Start date: February 26, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of inhibiting xanthine oxidase with allopurinol in patients with chronic kidney disease in asymptomatic hyperuricemia endothelial injury and vascular repair mechanisms.

NCT ID: NCT04976010 Completed - Clinical trials for Cardiovascular Diseases

Single Cell Leukocyte Landscapes and Cardiovascular Risk in Children With Chronic Kidney Disease

Start date: July 17, 2021
Phase:
Study type: Observational

Chronic kidney disease (CKD) is associated with an increased cardiovascular mortality. In particular children with early-onset CKD have a lifelong increased risk to suffer from cardiovascular disease (CVD). Therefore, children with CKD deserve our attention. The immune system in children with CKD is disturbed, exhibiting pro-inflammatory features. Therefore, we aim to learn more about the characteristics of the immune system in early-onset CKD. In this project PBMC of pediatric CKD patients and age-matched healthy controls will be analysed and compared using CITE-Seq as a multimodal scRNAseq phenotyping method. All patients will be clinically characterized to integrate cardiovascular and immunological data.

NCT ID: NCT04971252 Completed - Clinical trials for Renal Disorder Associated With Type II Diabetes Mellitus

Type 2 Diabetes Mellitus and Chronic Kidney Disease

Start date: July 7, 2021
Phase:
Study type: Observational [Patient Registry]

To investigate the effect of co existance of diabetes mellitus and chronic kidney disease on basic coagulation profile in comparison with diabetic patients with normal kidney function and non diabetic patients with chronic kidney disease

NCT ID: NCT04959578 Completed - Clinical trials for Anemia of Chronic Kidney Disease

Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease

Start date: February 1, 2018
Phase: Phase 4
Study type: Interventional

The present study was designed to determine whether or not darbepoetin alfa is non-inferior to recombinant human erythropoietin in the treatment of anemia in children with chronic kidney disease stage 3-5 (on or not on dialysis).

NCT ID: NCT04958759 Completed - Clinical trials for Chronic Kidney Diseases

Functional Inspiratory Muscle Training in Chronic Kidney Disease

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Effects of functional inspiratory muscle training by telerehabilitation on respiratory and peripheral functions, functional capacity, diaphragm thickness and mobility, posture, quality of life, cognitive function, fatigue, physical activity, endothelial function and aortic stiffness in patients with chronic kidney disease will be investigated.

NCT ID: NCT04940117 Completed - Clinical trials for Chronic Kidney Diseases

Effects of the Eefooton on eGFR and QoL in Chronic Kidney Disease Patients.

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Chronic renal failure is a chronic and progressive disease with a poor prognosis. In recent years, it can be found in many literature reports that traditional Chinese medicine therapy has obvious effects on early and mid-term chronic renal failure. It can not only improve clinical symptoms, but also block or delay the process of renal failure. It is relatively rare that compounds such as compounds. The side effects of drugs may be used in combination with compound drugs to improve clinical side effects and help patients improve their quality of life to complete the treatment course. It can provide clinicians with another choice in treatment. A previous study confirmed that the use of Eefooton oral solution of Chinese herbal medicine concentrate has a significant protective effect on the kidneys that have not undergone hemodialysis. Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism. The purpose of this clinical observation and research is to evaluate the eGFR changes in the renal function of patients with chronic kidney disease with the combination of Eefooton oral solution and commonly used chemical drugs.

NCT ID: NCT04939870 Completed - Clinical trials for Cardiovascular Diseases

Assessment of Protein Modification in Chronic Kidney Disease - Selected Clinical and Biochemical Aspects

Start date: January 1, 2015
Phase:
Study type: Observational

The studies included the effect of chronic kidney disease advancement on the accumulation of oxidative stress markers in plasma. In patients with end-stage renal disease, the effect of replacement therapy was also assessed. Therefore, the patient with chronic kidney disease was evaluated divided into three groups (chronic kidney disease at stage G3b-G4, peritoneal dialysis, hemodialysis). In addition, changes in the interrelationship between oxidative modifications, carbonyl and nitrogen stress, and the carbamylation resulting from the progression of kidney disease have been taken into account. This issue is related to the assessment of whether the protein modification types differentiate patients depending on the stage of chronic kidney disease and the method of renal replacement therapy. Protein modifications associated with oxidative stress are a part of the complications resulting from chronic kidney diseases, such as malnutrition, chronic inflammation, dyslipidemia, iron disorder, and calcium and phosphate disorders. Also, diseases of atherosclerosis aetiology are much higher frequency in patients with chronic kidney disease than in those with normal kidney function. Therefore, in the studies presented here, particular attention was paid to the effect of oxidative stress on chronic kidney disease complications in the aspect of cardiovascular damage. The specificity of atherosclerosis in patients with chronic kidney disease was evaluated by comparing groups of this type of patients with patients with ischemic heart diseases and normal renal function.